Floatz logo

IANALUMAB

Relapse Remitting Multiple Sclerosis

Novartis Pharmaceuticalsmonoclonal_antibodyPhase 2Dormant
D
29/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
14/ 100
Competitive Position
95/ 100

Competitive context

80 Active assets in the Relapse Remitting Multiple Sclerosis cohort.

Asset / SponsorPhaseRating
Fingolimod
TG Therapeutics, Inc.
Phase 4A
Natalizumab
Biogen
Phase 4BBB
Glatiramer
University Hospital, Montpellier
Phase 4BBB
Interferon ?1 (human fibroblast protein moiety)
Biogen
Phase 4BBB
2-BUTENEDIOIC ACID, (2E)-, DIMETHYL ESTER
University Hospital, Montpellier
Phase 4BBB

View all 50 →

Same molecule, other indications

IANALUMAB is also rated in:

idiopathic pulmonary fibrosisDormant
D
Indicative ·
29 / 100
View asset →
chronic lymphocytic leukemia/small lymphocytic lymphomaDormant
D
Indicative ·
23 / 100
View asset →
non-Hodgkin lymphomaDormant
D
Indicative ·
23 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →